Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted EPS of $9.55, down 5% Y/Y, missing the consensus of $10.10.
週四，再生元製藥公司（納斯達克股票代碼：REGN）公佈的第一季度調整後每股收益爲9.55美元，同比下降5％，未達到10.10美元的共識。
The company reported sales of $3.15 billion, missing the consensus of $3.22 billion.
該公司報告的銷售額爲31.5億美元，未達到32.2億美元的共識。
First quarter 2024 revenues decreased by 1%; excluding Ronapreve (COVID-19 antibody), revenues increased by 7%.
2024年第一季度收入下降了1％；不包括Ronapreve（COVID-19 抗體），收入增長了7％。
Eylea US sales fell 16% to $1.2 billion, primarily due to changing market dynamics, resulting in lower volumes and a lower net selling price.
Eylea美國銷售額下降了16％，至12億美元，這主要是由於市場動態的變化，導致銷量減少和淨銷售價格降低。
Eylea HD sales reached $200 million, and overall, Eylea sales fell 2% to $1.4 billion.
Eylea HD的銷售額達到2億美元，總體而言，Eylea的銷售額下降了2％，至14億美元。
Continued Dupixent strength compensated for stagnant Eylea sales, which Sanofi SA (NASDAQ:SNY) records, jumped a currency-adjusted 24.9% to 2.84 billion euros.
Dupixent的持續走強彌補了Eylea銷售的停滯，賽諾菲股份公司（納斯達克股票代碼：SNY）創紀錄的經匯率調整後增長了24.9％，至28.4億歐元。
As a result, Regeneron's collaboration cut from Sanofi rose 14% to $910 million.
結果，Regeneron從賽諾菲削減的合作額增長了14％，達到9.1億美元。
Regeneron's oncology treatment Libtayo continued its rise. Sales were up 49% to $264 million.
Regeneron的腫瘤治療藥物Libtayo繼續上漲。銷售額增長了49％，達到2.64億美元。
Taking a dig at the obesity space, during a Q1 earnings conference call, George Yancopoulos, Regeneron's co-founder, president, and chief scientific officer, said, "Our antibodies to myostatin-related pathways may prevent this muscle loss."
Regeneron的聯合創始人、總裁兼首席科學官喬治·揚科普洛斯在第一季度業績電話會議上深入探討了肥胖領域，他說：“我們針對肌抑素相關途徑的抗體可以防止這種肌肉流失。”
GLP/GIP receptor agonists have been associated with muscle loss.
GLP/GIP 受體激動劑與肌肉流失有關。
"Indeed, our data in obese non-human primates show that combining semaglutide with trevogrumab, our antibody targeting myostatin, with or without garetosmab, our antibody targeting activin A or myostatin 2, demonstrated a comparable reduction in body weight at week 20 relative to semaglutide monotherapy, but with improved quality of weight loss, resulting in more fat loss while preserving or even increasing lean mass."
“事實上，我們在肥胖的非人靈長類動物身上的數據表明，與索瑪魯肽單一療法相比，我們的靶向肌抑制素的抗體特雷伏格魯單抗，無論是否使用garetosmab，我們的靶向激活素A或肌抑素2的抗體，在第20周的體重下降幅度與索瑪魯肽單一療法相當，但減肥質量有所改善，從而在保持甚至增加瘦肉質量的同時減少更多的脂肪。”
Part A of the proof of concept study in healthy volunteers intended to demonstrate the safety of a higher dose of trevogrumab has completed enrollment.
旨在證明更高劑量特雷沃格魯單抗安全性的健康志願者概念驗證研究的A部分已經完成了入組。
Over 400 subjects, including healthy volunteers and sarcopenic patients, have been dosed with trevogrumab, with no meaningful safety or tolerability concerns observed to date.
包括健康志願者和肌肉減少症患者在內的400多名受試者已經服用了trevogrumab，迄今未觀察到任何有意義的安全性或耐受性問題。
Part B of the study, which will evaluate muscle preservation antibodies in combination with semaglutide in obese participants, remains on track to start enrolling midyear.
該研究的B部分將評估肥胖參與者體內的肌肉保護抗體與索瑪魯肽聯合使用，該部分仍有望在年中開始入學。
Regeneron expects to report topline results in the second half of 2025.
Regeneron預計將在2025年下半年公佈業績。
Price Action: REGN shares are up 3.5% at $935.20 at last check Thursday.
價格走勢：週四最後一次檢查時，REGN股價上漲3.5％，至935.20美元。
Now Read: Another Boeing Whistleblower Dies, This Time Due To Sudden Infection
立即閱讀：另一名波音舉報人死亡，這次是由於突然感染
Photo: Shutterstock
照片：Shutterstock
譯文內容由第三人軟體翻譯。